Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRingborg, Ulrik
dc.contributor.authorCelis, Julio E.
dc.contributor.authorTabernero, Josep
dc.contributor.authorSchüz, Joachim
dc.contributor.authorGarralda Cabanas, Elena
dc.contributor.authorNuciforo, Paolo Giovanni
dc.contributor.authorWren, Amanda
dc.contributor.authorBerns, Anton
dc.contributor.authorHeitor, Manuel
dc.date.accessioned2022-05-02T12:46:49Z
dc.date.available2022-05-02T12:46:49Z
dc.date.issued2021-10
dc.identifier.citationRingborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schüz J, et al. The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 Oct;15(10):2507–43.
dc.identifier.issn1878-0261
dc.identifier.urihttps://hdl.handle.net/11351/7434
dc.descriptionClinical/prevention trials; Comprehensive cancer centres; Outcomes research
dc.description.abstractKey stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high-quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research across the entire cancer continuum to support the development of personalized/precision cancer medicine in Europe. The three pillars of the recommended European infrastructures – namely translational research, clinical/prevention trials and outcomes research – were pondered at length. Speakers addressing the future needs of translational research focused on the prospects of multiomics assisted preclinical research, progress in Molecular and Digital Pathology, immunotherapy, liquid biopsy and science data. The clinical/prevention trial session presented the requirements for next-generation, multicentric trials entailing unified strategies for patient stratification, imaging, and biospecimen acquisition and storage. The third session highlighted the need for establishing outcomes research infrastructures to cover primary prevention, early detection, clinical effectiveness of innovations, health-related quality-of-life assessment, survivorship research and health economics. An important outcome of the Summit was the presentation of the Porto Declaration, which called for a collective and committed action throughout Europe to develop the cancer research infrastructures indispensable for fostering innovation and decreasing inequalities within and between member states. Moreover, the Summit guidelines will assist decision making in the context of a unique EU-wide cancer initiative that, if expertly implemented, will decrease the cancer death toll and improve the quality of life of those confronted with cancer, and this is carried out at an affordable cost.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesMolecular Oncology;15(10)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMedicina - Investigació
dc.subjectMedicina personalitzada
dc.subjectCàncer - Prevenció
dc.subject.meshBiomedical Research
dc.subject.meshNeoplasms
dc.subject.mesh/prevention & control
dc.subject.meshPrecision Medicine
dc.titleThe Porto European Cancer Research Summit 2021
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/1878-0261.13078
dc.subject.decsinvestigación biomédica
dc.subject.decsneoplasias
dc.subject.decs/prevención & control
dc.subject.decsmedicina de precisión
dc.relation.publishversionhttps://doi.org/10.1002/1878-0261.13078
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Ringborg U] Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden. European Academy of Cancer Sciences, Stockholm, Sweden. [Berns A] European Academy of Cancer Sciences, Stockholm, Sweden. The Netherlands Cancer Institute, Amsterdam, The Netherlands. [Celis JE] European Academy of Cancer Sciences, Stockholm, Sweden. Danish Cancer Society Research Centre, Copenhagen, Denmark. [Heitor M] Ministry for Science, Technology and Higher Education, Lisbon, Portugal. [Tabernero J, Garralda E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Cancer Core Europe, Amsterdam, The Netherlands. [Schüz J] International Agency for Research on Cancer (IARC/WHO), Lyon, France. Cancer Prevention Europe, Lyon, France. [Nuciforo P, Wren A] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid34515408
dc.identifier.wos000695179300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record